The 10-second takeaway
For the quarter ended March 31 (Q1), MAKO Surgical beat slightly on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. GAAP loss per share dropped.
Margins increased across the board.
MAKO Surgical booked revenue of $24.8 million. The nine analysts polled by S&P Capital IQ predicted a top line of $24.4 million on the same basis. GAAP reported sales were 26% higher than the prior-year quarter's $19.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.21. The 10 earnings estimates compiled by S&P Capital IQ predicted -$0.19 per share. GAAP EPS were -$0.21 for Q1 against -$0.28 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 73.6%, 150 basis points better than the prior-year quarter. Operating margin was -36.0%, much better than the prior-year quarter. Net margin was -38.8%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $28.7 million. On the bottom line, the average EPS estimate is -$0.27.
Next year's average estimate for revenue is $126.0 million. The average EPS estimate is -$0.65.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,201 members out of 1,246 rating the stock outperform, and 45 members rating it underperform. Among 266 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 255 give MAKO Surgical a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $14.57.
Is MAKO Surgical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add MAKO Surgical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends MAKO Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Do You Still Own MAKO Surgical?
MAKO Surgical is trading near 52-week-highs, but that's not why one Fool thinks it's a bad idea to own the stock right now.
What Medtronic Needs to Beat the Stryker-MAKO Merger
Medtronic is a giant in the medical-device industry, and even though Stryker's acquisition of MAKO Surgical will present some challenges, it can still stay on top.
MAKO Surgical Q3 Revenues Drop, Net Loss Deepens
The bottom-line shortfall is more than three times that of Q3 2012.